1027P 1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer
| Autor: | Verschraegen, C., Andric, Z.G., Ciuleanu, T-E., Moiseenko, F.V., Makharadze, T., Shevnia, S., Oleksiienko, A., Yanez Riuz, E., Kim, S.H., Ahn, K.Y., Park, T.H., Park, S., Baek, E.H., Kwon, S., Ju, H.A., Lee, S.J., Kim, H.A., Lee, E.K., Ohe, Y. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1024-S1025 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|